Nisa Investment Advisors
CCCC icon

Nisa Investment Advisors’s C4 Therapeutics CCCC Stock Holding History

Nisa Investment Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$729 Hold
156
– – ﹤0.01% 2899
2026
Q1 		$410 Hold
156
– – ﹤0.01% 2886
2025
Q4 		$298 Hold
156
– – ﹤0.01% 2884
2025
Q3 		$346 Sell
156
-274
-64% -$658 ﹤0.01% 2900
2025
Q2 		$615 Buy
430
+267
+164% +$388 ﹤0.01% 2836
2025
Q1 		$261 Buy
+163
New +$486 ﹤0.01% 2893
2024
Q4 		– Sell
-165
Closed -$941 – 3010
2024
Q3 		$941 Buy
+165
New +$993 ﹤0.01% 2593
2023
Q4 		– Sell
-490
Closed -$911 – 2660
2023
Q3 		$911 Sell
490
-32
-6% -$98 ﹤0.01% 2410
2023
Q2 		$1.44K Sell
522
-6
-1% -$19 ﹤0.01% 2388
2023
Q1 		$2K Sell
528
-2,562
-83% -$15.1K ﹤0.01% 2313
2022
Q4 		$18K Hold
3,090
– – ﹤0.01% 2080
2022
Q3 		$30K Hold
3,090
– – ﹤0.01% 1930
2022
Q2 		$23K Buy
3,090
+2,600
+531% +$22.9K ﹤0.01% 2007
2022
Q1 		$12K Sell
490
-1,130
-70% -$27.4K ﹤0.01% 2162
2021
Q4 		$40K Buy
1,620
+930
+135% +$36.8K ﹤0.01% 1784
2021
Q3 		$31K Hold
690
– – ﹤0.01% 2012
2021
Q2 		$26K Buy
+690
New +$24.7K ﹤0.01% 2081

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nisa Investment Advisors's CCCC Position: Q2 2026 in Review

Nisa Investment Advisors held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 156 shares worth $729. The position accounts for ﹤0.01% of the portfolio, ranked #2899.

Nisa Investment Advisors first reported a position in CCCC in Q2 2021 and has held it in 17 quarters since. The position peaked at $40K in Q4 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Nisa Investment Advisors held 156 shares of C4 Therapeutics worth $729 as of Q2 2026.
  • Nisa Investment Advisors left its C4 Therapeutics share count unchanged in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2899 holding.
  • Nisa Investment Advisors first reported a position in C4 Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • Nisa Investment Advisors's C4 Therapeutics position peaked at $40K in Q4 2021.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.